These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1224004)

  • 1. Effects of molindone on central dopaminergic neuronal activity and metabolism: similarity to other neuroleptics.
    Bunney BS; Roth RH; Aghajanian GK
    Psychopharmacol Commun; 1975; 1(4):349-58. PubMed ID: 1224004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential dose- and time-dependent effects of molindone on dopamine neurons of rat brain: mediation by irreversible inhibition of monoamine oxidase.
    Meller E; Friedman E
    J Pharmacol Exp Ther; 1982 Mar; 220(3):609-15. PubMed ID: 6121048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment.
    Skarsfeldt T
    Synapse; 1992 Jan; 10(1):25-33. PubMed ID: 1346943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of amfonelic acid with antipsychotic drugs on dopaminergic neurons.
    Gudelsky GA; Nwajei EE; Defife K; Nash JF
    Synapse; 1992 Dec; 12(4):304-11. PubMed ID: 1361248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced stereotyped response to amphetamine after pretreatment with small doses of molindone.
    Conway P; Uretsky NJ
    Neuropharmacology; 1983 May; 22(5):579-86. PubMed ID: 6308493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity.
    Bunney BS; Walters JR; Roth RH; Aghajanian GK
    J Pharmacol Exp Ther; 1973 Jun; 185(3):560-71. PubMed ID: 4576427
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens.
    Ichikawa J; Meltzer HY
    J Pharmacol Exp Ther; 1991 Jan; 256(1):348-57. PubMed ID: 1703232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies.
    Wachtel SR; White FJ
    J Pharmacol Exp Ther; 1988 Jan; 244(1):410-6. PubMed ID: 2891845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiological and pharmacological characterization of identified nigrostriatal and mesoaccumbens dopamine neurons in the rat.
    Clark D; Chiodo LA
    Synapse; 1988; 2(5):474-85. PubMed ID: 2903568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine.
    Meltzer HY; Chai BL; Thompson PA; Yamamoto BK
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1452-61. PubMed ID: 8138957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens.
    Compton DR; Johnson KM
    J Pharmacol Exp Ther; 1989 Feb; 248(2):521-30. PubMed ID: 2918468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat.
    McMillen BA; McDonald CC
    Neuropharmacology; 1983 Mar; 22(3):273-8. PubMed ID: 6133232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis.
    Hara S; Mukai T; Kurosaki K; Kuriiwa F; Endo T
    Arch Toxicol; 2002 Oct; 76(10):596-605. PubMed ID: 12373456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat.
    Fà M; Mereu G; Ghiglieri V; Meloni A; Salis P; Gessa GL
    Synapse; 2003 Apr; 48(1):1-9. PubMed ID: 12557266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function.
    Matthews RT; McMillen BA; Sallis R; Blair D
    J Pharmacol Exp Ther; 1986 Oct; 239(1):124-31. PubMed ID: 2876091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological evaluation of a partial agonist of dopamine receptors.
    Piercey MF; Hoffmann WE; Vogelsang GD; Travis M
    J Pharmacol Exp Ther; 1987 Oct; 243(1):391-6. PubMed ID: 3668865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.
    Meller E
    Psychopharmacology (Berl); 1982; 76(3):222-7. PubMed ID: 6808540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study.
    Blackburn TP; Suzuki K; Ashby CR
    Synapse; 2006 Jun; 59(8):502-12. PubMed ID: 16565966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds.
    Saller CF; Salama AI
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Oct; 334(2):125-32. PubMed ID: 2878374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of molindone and fluphenazine on the brain concentration of some phenolic and catecholic amines in the mouse and the rat.
    Juorio AV
    Br J Pharmacol; 1980 Nov; 70(3):475-80. PubMed ID: 6777007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.